This study investigates the benefits and safety of the use of directSTIM DBS system within its Intended Use, to deliver Deep Brain Stimulation therapy to patients suffering from Essential Tremor whose motor symptoms are no longer optimally controlled through pharmaceutical treatment.~The objective of this study is to show that directSTIM is not inferior to competitor DBS Systems at alleviating postural or kinetic symptoms of Essential Tremor through the delivery of Deep Brain Stimulation therapy.~Data to be analyzed will be collected from ET patients referred for DBS surgery, who chose to get the directSTIM DBS System implanted after discussing its risks and benefits with their clinician.~All procedures involving the patient and the device follow the standard of care in place at the site for DBS.
This is a prospective, multi-center, single arm post-market clinical follow-up study.~The present study investigates a CE-marked product that will be used per its Intended Use, and all procedures involved follow the standard of care.~This is an observational study to provide clinical evidence in support of DBS effectiveness in the treatment of ET when delivered by the directSTIM DBS system.~Twenty-one patients will be enrolled in this study. Subjects selected to participate in the study will be ET patients referred to uni- or bilateral DBS implant who meet the inclusion criteria and none of the exclusion criteria.~Primary effectiveness variables will be measured at baseline for the identification of the worst limb (most affected by the disease), then 3 months post-surgery. Safety events will be collected between implant and 3-month visit, to evaluate potential confounding factors.~After completing the 3-month visit, subjects will exit the study, and continue to be followed by their physician per usual care.~Study will be conducted at minimum 3 centers in Europe.